Clinical Trial Update: Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating pirtobrutinib in combination with venetoclax for patients with chronic lymphocytic leukemia or s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Kerry Rogers | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING